| Cinieri, Saverio |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Not yet recruiting | 2 | 206 | Europe | Atezolizumab, Bevacizumab | Fondazione Ricerca Traslazionale | Non-small-cell Lung Cancer Patients | 05/22 | 04/23 | | |
GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy |
|
|
| Recruiting | 2 | 168 | Europe | Palbociclib | Consorzio Oncotech | Metastatic Breast Cancer, Locally Advanced Breast Cancer | 07/23 | 07/23 | | |
AZALEA, NCT06690840: Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients |
|
|
| Not yet recruiting | 2 | 45 | Europe | Atezolizumab in combination with Cyclophosphamide and Vinorelbine | European Institute of Oncology | Triple Negative Breast Cancer | 12/26 | 02/27 | | |
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy |
|
|
| Recruiting | 2 | 173 | Europe | Cetuximab, Erbitux, Avelumab, Bavencio | University of Campania "Luigi Vanvitelli" | Metastatic Colorectal Cancer | 07/25 | 07/25 | | |
MITO 35a, NCT05233982: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer |
|
|
| Recruiting | 2 | 200 | Europe | Olaparib Oral Product | National Cancer Institute, Naples | Ovarian Cancer | 01/26 | 01/26 | | |
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer |
|
|
| Recruiting | 2 | 220 | Europe | Giredestrant, Triptorelin, Anastrozole | ETOP IBCSG Partners Foundation, Hoffmann-La Roche | Breast Cancer | 06/26 | 06/26 | | |
NCT04810182: Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS |
|
|
| Completed | N/A | 192 | Europe | Regorafenib 40 MG Oral Tablet [STIVARGA] | Istituto Oncologico Veneto IRCCS | Glioblastoma Multiforme | 12/23 | 12/23 | | |
NCT04416672: Validation of the Italian Version of the PRO-CTCAE |
|
|
| Recruiting | N/A | 3675 | Europe | PRO-CTCAE items | National Cancer Institute, Naples | Malignant Neoplasms | 07/24 | 07/24 | | |
| Recruiting | N/A | 3000 | Europe | | Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l. | Solid Tumours in Advanced Stages | 10/26 | 10/26 | | |
| Recruiting | N/A | 3600 | Europe | | Italian Association Neuroendocrine Tumors | Gastro-entero Pancreatic Neuroendocrine Tumors | 07/27 | 07/32 | | |
| Recruiting | N/A | 1000 | Europe | | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l. | Breast Neoplasms, Pregnancy, Fertility Preservation | 11/27 | 11/32 | | |
